Company

Theradiag SA

Headquarters: Marne-la-Vallee, France

Employees: 59

CEO: Mr. Bertrand De Castelnau

Euronext: ALTER

Market Cap

€28.9 Million

EUR as of July 1, 2023

US$31.6 Million

Market Cap History

Theradiag SA market capitalization over time

Evolution of Theradiag SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Theradiag SA

Detailed Description

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Theradiag SA has the following listings and related stock indices.


Stock: Euronext: ALTER wb_incandescent

Details

Headquarters:

14 rue Ambroise Croizat

CS 90136 Croissy Beaubourg cedex 2

Marne-la-Vallee, 77435

France

Phone: 33 1 64 62 10 12

Fax: 33 1 64 62 09 12